AI-Guided Precision Medicine: A European Biotechnology Thematic Network Association Perspective on Multi-Omics, Digital Sensors, Medical Assessment, and Ethical-Regulatory Challenges
Eurobiotech Journal, cilt.10, sa.4, ss.270-286, 2026 (ESCI, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 10 Sayı: 4
- Basım Tarihi: 2026
- Doi Numarası: 10.2478/ebtj-2026-0020
- Dergi Adı: Eurobiotech Journal
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, Directory of Open Access Journals, Business Source Ultimate (EBSCO)
- Sayfa Sayıları: ss.270-286
- Anahtar Kelimeler: Artificial intelligence, digital sensors, health governance, multi-omics integration, precision medicine
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Erciyes Üniversitesi Adresli: Evet
Özet
Artificial intelligence (AI) is increasingly integrated with genomics, multi-omics, pharmacogenomics, liquid biopsy, and digital biosensing, yet the data infrastructure, governance practices, and evidence standards remain uneven. This European Biotechnology Thematic Network Association (EBTNA) position paper includes peer-reviewed studies, regulatory reviews, and official policy surveys up to October 2026, to gauge clinical maturity and set out priorities for a responsible implementation across Europe. The review aims to identify critical gaps in governance and workforce readiness and then propose concrete lines of action. Across the World Health Organization (WHO) European Region, only 8% of Member States have a health-specific AI strategy, 24% provide in-service AI training for the health workforce, and fewer than 10% have drafted liability standards for AI in health. At the same time, the Food and Drug Administration (FDA) has authorized 903 AI-enabled medical devices as of August 2024, and 97.1% were cleared through the 510(k) pathway, for which clinical-data requirements depend on intended use and technological characteristics. Therefore, the EBTNA proposes seven lines of action whose responsible integration should link technical performance to clinical utility, equity, transparency, and continuous oversight. The European biomedical community should push for active governance to develop AI-driven precision medicine. This position paper explains the scientific rationale, provides the regulatory analysis, and lays out strategic proposals for transition.